文献速递消化道肿瘤与早癌消化内镜

9种定量粪便免疫化学试验用于结直肠癌筛查的诊断性能直接比较

Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening.
PubMed 文献 · Gastroenterology · 2017-09-25

该研究在德国筛查结肠镜人群中,对1667例合格参与者的冻存粪便样本平行使用9种定量粪便免疫化学试验(FIT)检测血红蛋白,比较其检出进展期肿瘤(AN)的敏感性和特异性。结果显示,按厂商预设阈值或统一阈值时各FIT敏感性、特异性差异较大;但将阈值调整至特定特异性水平(99%、97%、93%)后,各FIT敏感性及阳性率趋于接近。作者认为筛查项目应基于目标特异性水平和可控阳性率选择阈值,而非直接采用厂商推荐阈值。

要点

  • 按厂商预设阈值,9种定量FIT检出AN的敏感性为21.8%-46.3%,特异性为85.7%-97.7%。
  • 调整阈值至特异性99%、97%、93%时,各FIT检出AN的敏感性分别约为14.4%-18.5%、21.3%-23.6%、30.1%-35.2%。
  • 作者建议筛查项目应基于目标特异性水平和可控阳性率选择阈值,而非直接使用厂商推荐阈值。

核心结论

  • 通过将阈值调整至特定特异性水平或阳性率,可在很大程度上克服定量FIT诊断性能的表观异质性。

研究设计与样本

  • 研究纳入2005年至2010年德国筛查结肠镜参与者,于结肠镜检查前采集粪便样本并冻存于-80°C至分析。
  • 样本解冻、匀质后平行使用9种定量FIT检测,结肠镜和病理报告由2名对检测结果设盲的受训研究助理独立评估。
  • 1667例符合纳入标准的参与者中,所有AN病例(n=216)和随机选取的300例无AN个体纳入分析。

主要发现

  • 使用厂商预设阈值(范围2.0-17.0 μg Hb/g粪便)时,检出AN的敏感性为21.8%-46.3%,特异性为85.7%-97.7%。
  • 使用统一阈值(15 μg Hb/g粪便)时,检出AN的敏感性为16.2%-34.3%,特异性为94.0%-98.0%。
  • 调整阈值使特异性达99%、97%、93%时,检出AN的敏感性分别为14.4%-18.5%、21.3%-23.6%、30.1%-35.2%,阳性率分别为2.8%-3.4%、5.8%-6.1%、10.1%-10.9%。

临床怎么用

  • 作者建议筛查项目应基于目标特异性水平和可控阳性率选择阈值,而非简单使用厂商推荐阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A variety of fecal immunochemical tests (FITs) for hemoglobin (Hb) are used in colorectal cancer screening. It is unclear to what extent differences in reported sensitivities and specificities reflect true heterogeneity in test performance or differences in study populations or varying pre-analytical conditions. We directly compared the sensitivity and specificity values with which 9 quantitative (laboratory-based and point-of-care) FITs detected advanced neoplasms (AN) in a single colorectal cancer screening study. METHODS: Pre-colonoscopy stool samples were obtained from participants of screening colonoscopy in Germany from 2005 through 2010 and frozen at -80°C until analysis. The stool samples were thawed, homogenized, and used for 9 different quantitative FITs in parallel. Colonoscopy and histology reports were collected from all participants and evaluated by 2 independent, trained research assistants who were blinded to the test results. Comparative evaluations of diagnostic performance for AN were made at preset manufacturers' thresholds (range, 2.0-17.0 μg Hb/g feces), at a uniform threshold (15 μg Hb/g feces), and at adjusted thresholds yielding defined levels of specificity (99%, 97%, and 93%). RESULTS: Of the 1667 participants who fulfilled the inclusion criteria, all cases with AN (n = 216) and 300 randomly selected individuals without AN were included in the analysis. Sensitivities and specificities for AN varied widely when we used the preset thresholds (21.8%-46.3% and 85.7%-97.7%, respectively) or the uniform threshold (16.2%-34.3% and 94.0%-98.0%, respectively). Adjusting thresholds to yield a specificity of 99%, 97%, or 93% resulted in almost equal sensitivities for detection of AN (14.4%-18.5%, 21.3%-23.6%, and 30.1%-35.2%, respectively) and almost equal positivity rates (2.8%-3.4%, 5.8%-6.1%, and 10.1%-10.9%, respectively). CONCLUSIONS: Apparent heterogeneity in diagnostic performance of quantitative FITs can be overcome to a large extent by adjusting thresholds to yield defined levels of specificity or positivity rates. Rather than simply using thresholds recommended by the manufacturer, screening programs should choose thresholds based on intended levels of specificity and manageable positivity rates.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gies A, Cuk K, Schrotz-King P, et al. Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening. Gastroenterology. 2017. PMID: 28958859. doi:10.1053/j.gastro.2017.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。